Phase I Study of Repeated Intraepithelial Delivery of Adenoviral p53 in Patients With Dysplastic Oral Leukoplakia

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 5, 2009, Pages 1074-1082

  Zhang, Songtao ^a   Li, Yi ^a   Li, Longjiang ^a   Zhang, Yuanyuan ^b   Gao, Ning ^a   Zhang, Zhuang ^a   Zhao, Hongwei ^a  

^a SICHUAN UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GENDICINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN BCL 2; PROTEIN P21;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD CHEMISTRY; CELL INFILTRATION; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEMATOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INJECTION PAIN; LEUKOCYTOSIS; LEUKOPENIA; LEUKOPLAKIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; TRANSIENT FEVER; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME; URINALYSIS; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADULT; AGED; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 64149107093     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2008.06.079     Document Type: Article

References (43)

1. Kramer I.R., Lucas R.B., Pindborg J.J., et al. Definition of leukoplakia and related lesions: An aid to studies on oral precancer. Oral Surg 46 (1978) 518
2. Axell T., Pindborg J.J., Smith C.J., et al. Oral white lesions with special reference to precancerous and tobacco-related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med 25 (1996) 49
3. Reibel J. Prognosis of oral pre-malignant lesions: Significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14 (2003) 47
4. Burkhardt A. Premaligne Veraenderungen der Mundschleimhaut. Der Pathologe 6 (1985) 126
5. Liu S.C., and Klein-Szanto A.J.P. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol 36 (2000) 145
6. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7
7. Forastiere A., Koch W., Trotti A., et al. Head and neck cancer. N Engl J Med 345 (2001) 1890
8. Epstein J.B., and Gorsky M. Topical application of vitamin A to oral leukoplakia. A clinical case series. Cancer 86 (1999) 921
9. Lodi G., Sardella A., Bez C., et al. Systematic review of randomized trials for the treatment of oral leukoplakia. J Dent Educ 66 (2002) 896
10. Laskaris G. How to treat oral leucoplakia. J Eur Acad Dermatol Venereol 14 (2000) 446
11. Chiesa F., Tradati N., Sala L., et al. Follow-up of oral leukoplakia after carbon dioxide laser surgery. Arch Otolaryngol Head Neck Surg 116 (1990) 177
12. Holmstrup P., Vedtofte P., Reibel J., et al. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 42 (2006) 461
13. Vora H.H., Trivedi T.I., Shukla S.N., et al. p53 expression in leukoplakia and carcinoma of the tongue. Int J Biol Markers 21 (2006) 74
14. Weinberg R.A. Tumor suppressor genes. Science 254 (1991) 1138
15. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323
16. Gallagher W.M., and Brown R. p53-oriented cancer therapeutics: Current progress. Ann Oncol 10 (1999) 139
17. Yoo G.H., Piechocki M.P., Oliver J., et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 114 (2004) 1871
18. Tango Y., Taki M., Shirakiya Y., et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci 95 (2004) 459
19. Inoue H., Shiraki K., Murata K., et al. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 14 (2004) 271
20. Ohashi M., Kanai F., Ueno H., et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut 44 (1999) 366
21. Irie A., Matsumoto K., Anderegg B., et al. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. Cancer Gene Ther 13 (2006) 298
22. Buller R.E., Shahin M.S., Horowitz J.A., et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther 9 (2002) 567
23. Han D.M., Huang Z.G., Zhang W., et al. Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: Phase I clinical trial and follow up [in Chinese]. Zhonghua Yi Xue Za Zhi 83 (2003) 2029
24. Swisher S.G., Roth J.A., Komaki R., et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9 (2003) 93
25. Pathology & genetics. Tumours of the head and neck, in World Health Organization Classification of Tumours (2005), International Agency for Research on Cancer, Lyon
26. Quist S.R., Wang-Gohrke S., Köhler T., et al. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 11 (2004) 547
27. Johnson K.T., Rödicker F., Heise K., et al. Adenoviral p53 gene transfer inhibits human Tenon's capsule fibroblast proliferation. Br J Ophthalmol 89 (2005) 508
28. Li W., Ding F., Zhang L., et al. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin Cancer Res 11 Pt 1 (2005) 8753
29. Shimizu M., Saitoh Y., and Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign and malignant human pancreatic tissues. Hum Pathol 21 (1990) 607
30. Lodi G., Sardella A., Bez C., et al. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 18 (2006) CD001829
31. Lee J.J., Hong W.K., Hittelman W.N., et al. Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res 6 (2000) 1702
32. Latonen L., and Laiho M. Cellular UV damage responses-Functions of tumor suppressor p53. Biochim Biophys Acta 1755 (2005) 71
33. Fuster J.J., Sanz-González S.M., Moll U.M., et al. Classic and novel roles of p53: Prospects for anticancer therapy. Trends Mol Med 13 (2007) 192
34. Pisters L.L., Pettaway C.A., Troncoso P., et al. : Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10 (2004) 2587
35. Lang F.F., Bruner J.M., Fuller G.N., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 21 (2003) 2508
36. Fujiwara T., Tanaka N., Kanazawa S., et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 1689
37. Clayman G.L., Frank D.K., Bruso P.A., et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5 (1999) 1715
38. Schuler M., Herrmann R., De Greve J.L., et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol 19 (2001) 1750
39. Waga S., Hannon G.J., Beach D., et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369 (1994) 574
40. Boulay J.L., Perruchoud A.P., Reuter J., et al. p21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. Cancer Gene Ther 7 (2000) 1215
41. Kuball J., Wen S.F., Leissner J., et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 20 (2002) 957
42. Pagliaro L.C., Keyhani A., Williams D., et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J Clin Oncol 21 (2003) 2247
43. Shiu M.N., Chen T.H., Chang S.H., et al. Risk factors for leukoplakia and malignant transformation to oral carcinoma: A leukoplakia cohort in Taiwan. Br J Cancer 82 (2000) 1871